Aardvark Therapeutics, Inc. Common Stock

Aardvark Therapeutics, Inc. Common Stock (AARD) Market Cap

Aardvark Therapeutics, Inc. Common Stock has a market capitalization of $120.6M.

Financials based on reported quarter end 2025-12-31

Price: $5.53

โ–ฒ 0.16 (2.98%)

Market Cap: 120.64M

NASDAQ ยท time unavailable

CEO: Tien-Li Lee

Sector: Healthcare

Industry: Biotechnology

IPO Date: 2025-02-13

Website: https://aardvarktherapeutics.com

Aardvark Therapeutics, Inc. Common Stock (AARD) - Company Information

Market Cap: 120.64M ยท Sector: Healthcare

Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Its lead product candidate is the ARD-101, an oral gut-restricted small-molecule agonist of certain targeting bitter taste receptors expressed in the gut lumen that is in Phase III clinical trial for hyperphagia associated with Prader-Willi Syndrome, as well as in Phase II clinical trial for hyperphagia associated with acquired hypothalamic obesity resultant from treatment of craniopharyngioma, including surgery or radiation. It also developing ARD-201, which is in Phase I clinical trial for the treatment of obesity. The company was incorporated in 2017 and is based in San Diego, California.

Analyst Sentiment

67%
Buy

Based on 8 ratings

Analyst 1Y Forecast: $26.00

Average target (based on 2 sources)

Consensus Price Target

Low

$6

Median

$35

High

$47

Average

$29

Potential Upside: 430.4%

Price & Moving Averages

Loading chart...

Fundamentals Overview

Loading fundamentals overview...

๐Ÿ“Š AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2025-12-31

"AARD reported revenue of $0 and a net loss of $17.6M (EPS: -$0.81) for the most recent period ended 2025-12-31. With revenue at zero in the dataset, net margin is not meaningfully measurable; however, profitability appears weak given the negative bottom line. Free cash flow was also negative at -$14.4M, driven by negative operating cash flow (-$14.4M), with no capex recorded and no dividends paid. On the balance sheet, the company had $117.2M in total assets versus $10.5M in total liabilities, resulting in $106.6M of equity. Net debt is -$46.6M, indicating net cash rather than leverage, which supports near-term balance sheet resilience. From a valuation and investor-return perspective, the stock price (around $3.54) is down sharply, with a -61.1% 1-year change and -73.2% YTD decline. With no dividends and no buyback data provided, shareholder value creation is primarily reflected through capital depreciation rather than cash returns. Analyst price targets are widely dispersed (low $6 to high $47; consensus $28), reflecting uncertainty around future operating turnaround and cash generation."

Revenue Growth

Neutral

Revenue is shown as $0 for the period, preventing assessment of growth and signaling materially limited top-line contribution (based on the provided dataset).

Profitability

Neutral

Net income is -$18.0M with EPS of -$0.81, indicating ongoing losses and no evidence of margin expansion in the reported period.

Cash Flow Quality

Neutral

Free cash flow is -$14.4M, driven by negative operating cash flow; no dividends and no capex are reported, implying cash burn rather than self-funding.

Leverage & Balance Sheet

Neutral

Net debt is -$46.6M (net cash position) and equity is large relative to liabilities, supporting financial resilience despite operating cash outflows.

Shareholder Returns

Neutral

Total shareholder value is negative primarily due to weak capital appreciation: -61.1% over 1 year and -73.2% YTD; dividends are zero and no buybacks are provided.

Analyst Sentiment & Valuation

Neutral

Valuation context is limited by missing standard valuation metrics; analyst targets are highly dispersed (low $6 to high $47), suggesting uncertainty about forward prospects.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Loading financial data and tables...
๐Ÿ“

SEC Filings (AARD)

ยฉ 2026 Stock Market Info โ€” Aardvark Therapeutics, Inc. Common Stock (AARD) Financial Profile